Skip to main content

Table 1 Overview of (potentially cholinergically mediated) AEs reported by younger adult subjects

From: Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study

MedDRA-preferred term

Placebo

n=9

15 mg

n=9

20 mg

n=9

25 mg

n=9

All HTL0018318

n=27

All AEs

5 (55.6)

8 (88.9)

6 (66.7)

6 (66.7)

20 (74.1)

All cholinergic AEs

1 (11.1)

5 (55.6)

5 (55.6)

6 (66.7)

16 (59.3)

Hypertension

0

0

0

0

0

Nausea

0

3 (33.3)

2 (22.2)

4 (44.4)

9 (33.3)

Diarrhoea

0

1 (11.1)

1 (11.1)

0

2 (7.4)

Vomiting

0

0

0

1 (11.1)

1 (3.7)

Hypersalivation

0

0

0

1 (11.1)

1 (3.7)

Hyperhidrosis

0

1 (11.1)

4 (44.4)

3 (33.3)

8 (29.6)

Constipation

0

0

0

0

0

Chills

0

1 (11.1)

0

0

1 (3.7)

Cold sweat

0

0

0

0

0

Feeling cold

0

0

1 (11.1)

0

1 (3.7)

Feeling hot

0

0

1 (11.1)

0

1 (3.7)

Feeling of body temperature change

0

0

0

0

0

Hot flush

0

0

1 (11.1)

2 (22.2)

3 (11.1)

Piloerection

0

0

2 (22.2)

0

2 (7.4)

Peripheral coldness

0

0

0

0

0

Insomnia

1 (11.1)

0

0

0

0

Dizziness

0

0

1 (11.1)

1 (11.1)

2 (7.4)

Muscle spasm

0

1 (11.1)

0

0

1 (3.7)

  1. Data are shown as number (percentage) of subjects reporting AEs